Company intelligence / Profile preview

Therapixel

Nice, Provence-Alpes-Côte d'Azur, Francetherapixel.com ↗

Ownership: Private
Development stage: Other

Overview

Therapixel’s MammoScreen platform is FDA-cleared and CE-marked for breast cancer screening, using AI to assist radiologists in interpreting 2D and 3D mammograms. Clinical studies have shown that it improves diagnostic accuracy, workflow efficiency, and confidence among radiologists. The technology is being adopted by major healthcare providers such as Mayo Clinic and Onsite Women’s Health across large networks in the US

Therapeutic areas: Oncology
Modalities: DeviceNon-pharmacological therapy (AI-based diagnostic support)
Industry: Digital Health Medical Devices

Partnerships

RamSoft Inc. (integration of MammoScreen into PowerServer™/OmegaAI® platforms)Onsite Women’s Health (deployment of MammoScreen across >150 locations)

Beyond the preview

Go deeper on Therapixel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Therapixel.

Explore the full profile